Q3 2026 Neuland Laboratories Ltd Earnings Call Transcript
Key Points
- Neuland Laboratories Ltd (BOM:524558) reported a total income of INR447.8 crores for Q3 FY26, marking an 11.4% increase year-on-year.
- The company has successfully commercialized a new CMS molecule, with shipments expected to contribute to future revenues.
- Neuland Laboratories Ltd (BOM:524558) has expanded its capacity for CMS projects, which is expected to drive growth in the coming quarters.
- The company is seeing increased interest from big pharma and biotech companies, particularly in its peptide manufacturing capabilities.
- Neuland Laboratories Ltd (BOM:524558) has maintained a strong net debt position, standing at negative INR202.6 crores, indicating financial stability.
- The gross margin for Q3 FY26 decreased to 52.1% from 53.2% in the same quarter last year, primarily due to product mix changes.
- EBITDA margin fell to 19% this quarter, impacted by increased overheads and labor costs.
- There was a significant impact on revenue from Paliperidone due to operational issues at the customer end, affecting shipments.
- The company's working capital has deteriorated due to higher inventories and uneven order flow, leading to higher receivables.
- Free cash flow was negative INR9.2 crores for the year, despite securing substantial advances from customers.
Ladies and gentlemen, good day, and welcome to the Neuland Laboratories Limited Q3 FY26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Ravi Udeshi from Ernst & Young. Thank you, and over to you, sir.
Thank you, Avirat. Good evening, friends. We welcome you to the Q3 and nine-months FY26 earnings conference call of Neuland Laboratories Limited. To take us through the results and to answer your questions, we have with us the top management from Neuland Laboratories, represented by Mr. Saharsh Davuluri, CEO and Managing Director; Mr. Abhijit Majumdar, CFO; and Mr. Sajit Emmanuel Medikonda, Head Corporate Planning and Strategy.
We will start the call with a brief overview of the financials by Mr. Abhijit Majumdar, and then Saharsh will give you the broad highlights of the business trends and what he is seeing in the market. And post that, we will open the call for the question-and-answer session. As usual, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
